Tide Pharmaceutical launches DPP-4 inhibitor oral hypoglycemic agent Vildagliptin Tablet
Vildagliptin Tablet, a new oral hypoglycemic agent developed by Beijing Tide Pharmaceutical Co., Ltd., has obtained drug registration approval notice issued by National Medical Products Administration of the People's Republic of China (approval number: State Drug Approval H20203163). Originally filed as a class 4 new chemical drug, this product is deemed to have passed generic drug quality and efficacy consistency evaluation, it was included on the 2017 National Reimbursement Drug List.
According to the statistics of International Diabetes Federation (IDF), approximately 463 million people of 20-79 age group worldwide suffer from diabetes in 2019. The global diabetes drug market has reached $83 billion, of which DPP-4 inhibitor oral hypoglycemic drug market exceeds $20 billion. As a new type of DPP-4 inhibitor, Vildagliptin increases the level and activity of endogenous GLP-1 by blocking DPP-4-mediated GLP-1 degradation in the body. It promotes insulin secretion and inhibits glucagon secretion to reduce fasting and postprandial blood glucose, and lowers HbA1c level. It is able to reverse the deteriorating pancreas islet function in diabetic patients while controlling blood glucose, showing a promising application prospect. Currently, it has been marketed in many countries as a monotherapy for type 2 diabetes. When the maximum tolerated dose of metformin monotherapy is unable to effectively control blood glucose, it can be combined with metformin in the treatment of type 2 diabetes; early combination with metformin can reduce the relative risk of initial treatment failure by 49%.
China is the world's largest country of diabetes with 116 million patients in 2019. The approval of this important oral hypoglycemic agent will further strengthen and consolidate the predominant position of Tide Pharmaceutical in the field of diabetes. It can form a product portfolio with commercially available products to jointly develop the chronic disease field of huge market potential.